Denali Therapeutics Inc. (NASDAQ:DNLI) Stock Has Average Target Price of $35.85

by · The Markets Daily

Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the sixteen research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have given a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $35.85.

A number of analysts have commented on DNLI shares. Sanford C. Bernstein reiterated a “hold” rating on shares of Denali Therapeutics in a report on Monday, June 22nd. Stifel Nicolaus set a $41.00 price target on shares of Denali Therapeutics in a research report on Monday, June 22nd. Deutsche Bank Aktiengesellschaft upped their target price on shares of Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. UBS Group upped their price target on Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, Wall Street Zen raised shares of Denali Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 19th.

Get Our Latest Research Report on Denali Therapeutics

Insider Activity

In other news, insider Alexander O. Schuth sold 2,857 shares of Denali Therapeutics stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total value of $71,624.99. Following the completion of the transaction, the insider owned 281,763 shares in the company, valued at approximately $7,063,798.41. This trade represents a 1.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 9.70% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

Several institutional investors have recently modified their holdings of the company. Engineers Gate Manager LP lifted its holdings in Denali Therapeutics by 256.5% during the 2nd quarter. Engineers Gate Manager LP now owns 57,430 shares of the company’s stock worth $1,477,000 after buying an additional 41,320 shares during the last quarter. Integrated Wealth Concepts LLC boosted its holdings in shares of Denali Therapeutics by 2.7% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 102,241 shares of the company’s stock valued at $2,630,000 after buying an additional 2,687 shares in the last quarter. Allworth Financial LP boosted its holdings in shares of Denali Therapeutics by 555.0% in the 2nd quarter. Allworth Financial LP now owns 1,834 shares of the company’s stock valued at $47,000 after buying an additional 1,554 shares in the last quarter. Nykredit A S purchased a new position in shares of Denali Therapeutics in the 2nd quarter valued at $38,000. Finally, Corient Private Wealth LP purchased a new position in shares of Denali Therapeutics in the 2nd quarter valued at $301,000. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Stock Performance

NASDAQ:DNLI opened at $20.81 on Friday. Denali Therapeutics has a fifty-two week low of $13.75 and a fifty-two week high of $27.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.32 and a current ratio of 8.37. The company has a fifty day moving average of $23.02 and a two-hundred day moving average of $21.88. The stock has a market capitalization of $3.33 billion, a PE ratio of -7.33 and a beta of 1.01.

Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The company had revenue of $3.60 million during the quarter, compared to the consensus estimate of $2.15 million. During the same quarter last year, the firm posted ($0.72) EPS. As a group, research analysts forecast that Denali Therapeutics will post -2.67 earnings per share for the current fiscal year.

Denali Therapeutics Company Profile

(Get Free Report)

Denali Therapeutics Inc is a biotechnology company focused on discovering and developing medicines for patients with neurodegenerative diseases. The company is headquartered in South San Francisco, California, and was founded in 2013 by a team that included Chief Executive Officer Ryan Watts.

Denali’s research is built around its blood-brain barrier transport technologies, which are designed to help therapeutic molecules reach the brain. The company applies these technologies to potential treatments for conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, lysosomal storage disorders and other neurodegenerative diseases.

Its pipeline has included investigational therapies directed at targets such as LRRK2, TREM2 and RIPK1, as well as enzyme-replacement approaches intended to improve delivery of treatments to the central nervous system.

Featured Stories